← Human Trials & Peer-Reviewed Studies
Somatostatin-analog effect on pancreatic fistula after radical gastrectomy: a pilot randomized controlled trial
Plain-language guide to PMID 36745222 (2023): pilot randomized controlled trial study of Somatostatin in 123 patients, pancreatitis (after the acute phase).
Key Facts
- PMID
- 36745222
- Journal
- Journal of cancer research and clinical oncology
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Sha S et al. (10 authors)
- DOI
- 10.1007/s00432-023-04584-7
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Somatostatin in the context of pancreatitis (after the acute phase), published as a randomized controlled trial.
Radical gastrectomy with D2 lymphadenectomy can trigger a high incidence of postoperative pancreatic fistula (POPF), which produces a poor clinical prognosis.
The researchers sought to evaluate the effect of somatostatin analogs (SSA) on POPF and clinical prognosis after radical gastrectomy.
Who Took Part
According to the abstract, 123 patients were involved.
A total of 123 patients with a high risk of POPF after radical gastrectomy (drainage fluid amylase concentration on a postoperative day [POD] 1 > 3 times the upper limit of normal serum amylase value) were randomly divided into the SSA group (n = 61) and the control group (n = 62).
How the Study Was Run
In design terms this was a randomized and pilot study.
Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.
It is described as a pilot, a small early test of whether a larger Somatostatin study would be practical.
The primary outcome was the incidence of POPF.
What Was Measured
The subject headings attached to it are Pancreatic Fistula, Somatostatin, Pilot Projects, Risk Factors, Gastrectomy, Postoperative Complications and Amylases.
Author keywords: Gastric cancer, Postoperative pancreatic fistula, Radical gastrectomy and Somatostatin analog.
What This Means in Plain Language
The paper is a randomized and pilot study of Somatostatin in 123 patients in people with pancreatitis (after the acute phase).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Journal of cancer research and clinical oncology), a journal based in Germany.
More context: the Somatostatin compound page, Pancreatitis (after the acute phase) research.
Our Notes on the Compound
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.